Profile
Sector:
HealthcareCountry:
United StatesIPO:
01 May 2012Website:
http://www.supernus.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 21 Jun 2024 20:20:00 GMTDividend
Analysts recommendations
Institutional Ownership
SUPN Latest News
SPN-817 is a novel, first-in-class highly selective acetylcholinesterase (AChE) inhibitor for epilepsy Company to host webcast today at 4:30 p.m. ET to discuss the interim data ROCKVILLE, Md.
NEW YORK , May 23, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") (NASDAQ: SUPN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Pomerantz LLP is currently looking into allegations from investors of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) and advises these investors to get in touch with Danielle Peyton at [email protected] or 646-581-9980, ext.
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2023 Earnings Call Transcript
Although the revenue and EPS for Supernus (SUPN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.43 per share a year ago.
Besides Wall Street's top -and-bottom-line estimates for Supernus (SUPN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ROCKVILLE, Md., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the fourth quarter and full year of 2023 on Tuesday, February 27, 2024.
Supernus Pharmaceuticals has experienced revenue growth every year since its IPO in 2021, reaching $667m in 2022. The company has expanded its product portfolio through acquisitions, including the purchase of Adamas for $850m. Q3 earnings beat expectations, with increased guidance for FY23 earnings and the resubmission of a New Drug Application for SPN-830.
- 1(current)
What type of business is Supernus Pharmaceuticals?
Supernus Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Rockville, Maryland, specializing in the development and commercialization of drugs for the treatment of central nervous system (CNS) disorders in neurology and psychiatry. It was founded in 2005. The company's product portfolio includes several commercialized drugs, as well as products at various stages of development: Oxtellar XR and Trokendi XR - the first extended-release formulations of oxcarbazepine and topiramate for once-daily use, intended for the treatment of epilepsy. Several patented CNS products are in development - SPN-812 (viloxazine hydrochloride), SPN-604 (extended-release oxcarbazepine) for the treatment of bipolar disorder, SPN-817 for the treatment of severe pediatric epilepsy disorders, SPN-809 for the treatment of depression.
What sector is Supernus Pharmaceuticals in?
Supernus Pharmaceuticals is in the Healthcare sector
What industry is Supernus Pharmaceuticals in?
Supernus Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry
What country is Supernus Pharmaceuticals from?
Supernus Pharmaceuticals is headquartered in United States
When did Supernus Pharmaceuticals go public?
Supernus Pharmaceuticals initial public offering (IPO) was on 01 May 2012
What is Supernus Pharmaceuticals website?
https://www.supernus.com
Is Supernus Pharmaceuticals in the S&P 500?
No, Supernus Pharmaceuticals is not included in the S&P 500 index
Is Supernus Pharmaceuticals in the NASDAQ 100?
No, Supernus Pharmaceuticals is not included in the NASDAQ 100 index
Is Supernus Pharmaceuticals in the Dow Jones?
No, Supernus Pharmaceuticals is not included in the Dow Jones index
When does Supernus Pharmaceuticals report earnings?
The next expected earnings date for Supernus Pharmaceuticals is 08 August 2024